Trademark Attorney / Law Firm

JAMES A. BANNEROT – Trademark Portfolio

JAMES A. BANNEROT specializes in Class 5 (Pharmaceuticals) trademark filings before the United States Patent and Trademark Office (USPTO), with 3 of 3 total filings concentrated in this category. The practice also covers Class 16 (Paper Goods) along with 2 other Nice Classification classes. Filing activity spans from 1994 to 1995. Currently, 0 trademarks are registered.

3 Total Trademarks
Loading...
By Date
By Name
Filter by Class:

MONOCHEM
MONOCHEM
Cancelled 1995
T-5 N.F.
T-5 N.F.
Cancelled 1994
DG-19
DG-19
Cancelled 1994

Practice Areas by Trademark Class

JAMES A. BANNEROT's trademark practice covers 2 Nice Classification classes, representing the range of industries and goods/services handled in their USPTO filings.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademark applications has JAMES A. BANNEROT filed?

JAMES A. BANNEROT has filed 3 trademark applications with the United States Patent and Trademark Office (USPTO).

What trademark classes does JAMES A. BANNEROT specialize in?

JAMES A. BANNEROT has filed trademarks across 2 Nice Classification classes. The most common practice areas include Class 5 (Pharmaceuticals), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

How long has JAMES A. BANNEROT been filing trademarks?

JAMES A. BANNEROT's trademark filing history with the USPTO spans from 1994 to 1995, covering 1 year of trademark practice. During this period, JAMES A. BANNEROT has handled 3 trademark applications.

What is JAMES A. BANNEROT's trademark registration success rate?

JAMES A. BANNEROT has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.